Analyst Joanne Wuensch of Citi maintained a Buy rating on Insulet, with a price target of $380.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joanne Wuensch’s rating is based on Insulet’s strong market position and promising growth prospects. The company is not only a leader but also a driver in its market, with a growth rate significantly outpacing the industry average. Insulet’s strategic initiatives, including the expansion into the Type 2 diabetes population and global markets, are expected to double its total addressable market to 17 million patients.
Furthermore, Insulet’s financial targets are ambitious yet achievable, with a projected 20% revenue CAGR and a significant increase in profitability. The company’s commitment to innovation is evident in its robust product pipeline, which includes the upcoming launches of Omnipod 5 and Omnipod 6, as well as a fully closed-loop system for Type 2 diabetes. These factors, combined with strategic investments in new facilities, position Insulet for sustained growth and justify the Buy rating.
In another report released on November 19, UBS also upgraded the stock to a Buy with a $400.00 price target.